Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx věcí,

kterým xx mění x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 58/2007 Sb. x. x. x č. 46/2008 Sb. m. x.

Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx xxx 1. xxxxx 2017 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx látek x xxxxx dopingu xxx xxx 2018 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx¹⁾.

X xxxxx xxxxxx Přílohy X xxxxxxxx xxxxxxx Parlament Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx podepsal xxxxxxx x xxxxxxx xxxx Přílohy X Xxxxxx republikou.

Nové znění Xxxxxxx X vstoupilo x xxxxxxxx v xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. ledna 2018. Pro Českou xxxxxxxxx vstoupilo xxxx xxxxx Xxxxxxx X x platnost xxx 5. xxxxxx 2019.

Dnem xxxxxx nového xxxxx Xxxxxxx X v xxxxxxxx xxxxxxxx platit xxxxx Xxxxxxx X xxxxxx xx 1. xxxxx 2017 x xxxxxxxxx pod č. 80/2017 Sb. m. s.

Xxxxxxxx xxxxx xxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.

XXXXXXX

XXXXXXXXXXXXX

XXXXXXXX

XXXXXXX ANTIDOPINGOVÝ XXXXX

XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX ROK 2018

XXXXXXXXXXX XXXXXXXX

Xxxxxxxxx xxxx Xxxxxxx xxxx xxxxxxxxx XXXX x xxxx publikován x angličtině x xxxxxxxxxxxxx.

X případě xxxxxxxxxxx xxxxxxxxx xxxx anglickou x xxxxxxxxxxxx xxxxx xxxx rozhodující anglická xxxxx.

Xxxxx Xxxxxx xxxx xxxxxx od 1. xxxxx 2018 

SEZNAM XXXXXXXXXX XXXXX X METOD XXXXXXX XXX ROK 2018

XXXXXXX XXXXXXXXXXXXX KODEX

Platný xx 1. xxxxx 2018

XXXXX A XXXXXX XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)

Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx kodexu všechny Xxxxxxxx xxxxx budou xxxxxxxxxx xx "Specifické xxxxx" xxxxx xxxxx xx skupin X1, X2, X4.4, S4.5 x X6(x) a Xxxxxxxxxx metod M1, X2 x M3.

ZAKÁZANÉ XXXXX

X0. NESCHVÁLENÉ LÁTKY

Jakákoliv xxxxxxxxxxxxx látka, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx sekcích Xxxxxxx x není xxxxxxxx xxxxxxxxx pro humánní xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx zdravotnickým regulačním xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx výzkumu xxxx po xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx pouze xxx xxxxxxxxxxx použití), xx xxxxxxxx xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx látky xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):

(x) Xxxxxxxx* XXX, zahrnující:

1-androstendiol (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

1-xxxxxxxxxxx (3α-xxxxxxx-5α-xxxxxxx-1-xx-17-xx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-diol);

bolasteron;

danazol ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-methyl-5α-androst-2-en-17ß-ol);

drostanolon;

ethylestrenol (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-hydroxy-17α-methylandrosta-1,4-dien-3-on);

metenolon;

methandriol;

metasteron (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestra-4,9-dien-3-on);

methyl-1-testosteron (17ß-hydroxy-17α-methyl-5α-androst-1-en-3-on);

methylnortestosteron (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.

x. Xxxxxxxxx** XXX, pokud xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (5α-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-diol);

19-norandrostendion (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x xxxxxx xxxxxxxxxx x xxxxxxx, xxxxxx, xxx xx x omezením xxxxx xx xx:

5α-xxxxxxxxx-3α,17α-xxxx;

5α-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxxxx-3ß,17α-xxxx;

5α-xxxxxxxxx-3ß,17ß-xxxx;

5ß-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxx-2-xx-17-xx;

xxxxxxx-4-xx-3α,17α-xxxx;

xxxxxxx-4-xx-3α,17ß-xxxx;

xxxxxxx-4-xx-3ß,17α-xxxx;

xxxxxxx-5-xx-3α,17α-xxxx;

xxxxxxx-5-xx-3α,17ß-xxxx;

xxxxxxx-5-xx-3ß,17α-xxxx;

4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Ostatní xxxxxxxxxx xxxxx, zahrnující:

Klenbuterol; xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (XXXX, např. xxxxxxx, LGD-4033, xxxxxxx x XXX140); xxxxxxx; xxxxxxx x zilpaterol, xxx xx x xxxxxxxx xxxxx xx xx.

Xxx účely xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx x xxxxx, xxxxxx tělo xxxxxxxx přirozeně xxxxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x látce, xxxxxx xxxx normálně xxxxxxxxx xxxxxxxxx.

X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX LÁTKY X XXXXXXXX

Xxxxxxxxxxx xxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx jsou zakázány:

1. Xxxxxxxxxxxxx (XXX) a xxxxxxxxxx ovlivňující erytropoézu, xxxxxx, ale xx x xxxxxxxx xxxxx xx ně:

1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx receptoru, např

darbepoetiny (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx na XXX (EPO-Fc, methoxypolyethylenglykol-epoetin xxxx (CERA)); XXX-xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx (xxxx. CNTO 530 a xxxxxxxxxxx).

1.2 Xxxxxxxxx prostředky xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx.

xxxxx; xxxxxx; xxxxxxxxxx; xxxxxxxxxx (FG-4592); xxxxx.

1.3 Xxxxxxxxxx XXXX, např.

K-11706.

1.4 Xxxxxxxxxx XXX - xxxx (XXX - β), např.

luspatercept; xxxxxxxxxxx.

1.5 Xxxxxxxx xxxxxxxxx opravného xxxxxxxxx. xxxx.

xxxxxx EPO; xxxxxxxxxxxxx EPO.

2. Xxxxxxxxx xxxxxxx x hormonové xxxxxxxxxx

2.1 Xxxxxxxxxxxxxxxxxx (XX) x luteinizační xxxxxx (XX) x xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, nafarelin x triptorelin, x xxxx.

2.2 Xxxxxxxxxxxxxx x xxxxxx uvolňující xxxxxxx, xxxx. xxxxxxxxxxxx.

2.3 Xxxxxxx xxxxxx (XX), jeho xxxxxxxxx a xxxxxxxxxx xxxxxxx, včetně, ale xx x omezením xxxxx na ně:

fragmenty xxxxxxxxx xxxxxxx, např. XXX-9604 a hGH 176-191; xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (XXXX) x jeho analoga, xxxx. XXX-1295, xxxxxxxxxx x xxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxxx x xxxxxxxx ghrelinu, např. xxxxxxxxxx, xxxxxxxxxx a xxxxxxxxxxx; xxxxxxxxxx peptidy xxxxxxxxx xxxxxxx (XXXX), xxxx. xxxxxxxxxxxx, XXXX-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, XXXX-5, XXXX-6 x xxxxxxxxx.

3. Xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx faktorů, xxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

xxxxxxxxxxxxx růstové xxxxxxx (XXXx);

xxxxxxxxxxxx xxxxxxx faktor (XXX);

xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1) x xxxx xxxxxxx

xxxxxxxxxx xxxxxxx xxxxxxx (XXX);

xxxxxxx xxxxxx xxxxxxxx z xxxxxxxx xxxxxxxx (PDGF);

thymosin- β4 x jeho xxxxxxxx, xxxx. XX-500;

xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX).

Xxxxx xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx faktorů xxxxxxxxxxx xxxxxxx nebo degradaci xxxxxxxx xxxxx, xxxxx x vaziva, xxxxxx xxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx typy xxxxxxxxx xxxxxx.

X3. BETA2- XXXXXXXX

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx xxxx-2 agonisté, včetně xxxxx xxxxxxxxx isomerů, xxxx xxxxxxxx.

Xxxxxxxx (xxx xx x xxxxxxxx xxxxx xx xx):

Xxxxxxxxx; xxxxxxxxxx; higenamin; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 800 xxxxxxxxxx xxxxx xxxxxxx 12 xxxxx xx xxxxxxxxx xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 mikrogramů xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 mikrogramů xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx v moči x koncentraci vyšší xxx 1000 xx/xx x přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx považována xx xxxxxxxxx laboratorní xxxxx, xxxxx xxxxxxxxx neprokáže xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx studií, xx xxxxxxxxxx výsledek xxx způsoben terapeutickou xxxxxx (x xxxxxxxx) xxxxx, xxx výše xxxxxxx maximální xxxxx.

X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx jsou xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx:

1. Inhibitory xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (androstatriendion);

androsta-3,5-dien-7-17-dion (arimistan);

4-androsten-3,6,17-trion (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, xxx xx x omezením pouze xx xx.

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx, xxx xx s xxxxxxxx pouze na xx.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

Xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx, ale xx x xxxxxxxx xxxxx na ně.

4. Xxxxx modifikující xxxxxx(x) xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, ale xx x omezením pouze xx xx.

5. Metaboiické xxxxxxxxxx:

5.1 Xxxxxxxxxx AMP-aktivované xxxxxxxxxxxxx (XXXX), xxxx. XXXXX; x Xxxxxxxx Xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx (PPARδ), xxxx. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) xxxxxxxx xxxxxx (GW1516, XX501516);

5.2 xxxxxxxx x xxxxxxxx xxxxxxxx;

5.3 xxxxxxxxx;

5.4 trimetazidin.

S5. XXXXXXXXX X XXXXXXXXX XXXXX

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx jsou xxxxxxxx, xxxxxx xxxx xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; xxxxxxxxxxxxxxx (xxxx. xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx); xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

• Xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxx; xxxxxxxxx; kanrenon; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx); xxxxxxxxxx a xxxxxxx (xxxx. tolvaptan), xxx xx x omezením xxxxx na xx.

X xxxxxxxx:

• xxxxxxxxxxxx; xxxxxxxxx a xxxxxx xxxxxx inhibitorů xxxxxxxxxxxxxx (xxxx. xxxxxxxxxxx x brinzolamidu)

• Lokálního xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxxx

Xxxxx jakéhokoliv množství xxxxx se xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, katin, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) ve Vzorku Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Xxx Xxxxxxx xx spojení x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx, xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx, pokud Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx xxxxx xxxxx k xx, xxxxx xxx xxxx xxxxxxx xx diuretikum xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. MANIPULACE X XXXX A XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, xxxxxxxx (xxxxxxxxx) xxxx heterologní xxxx xxxx červených xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx původu xx xxxxxxxxx xxxxxxx.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. xxxxxx xxxxxxxx xxxxxxxx xx hemoglobinu x xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), xxx xx x xxxxxxxx xxxxx xx ně. Inhalační xxxxxxxxxxxx kyslíkem zakázána xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx nebo s xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými xxxxxxx.

X2. XXXXXXXX A FYZIKÁLNÍ XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx Pokus x Podvod, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Vzorků xxxxxxxxxx při Xxxxxxxxx xxxxxxxx. To zahrnuje xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) moči, xxx ne s xxxxxxxx pouze xx xx.

2. Nitrožilní xxxxxx x/xxxx xxxxxxx xxxx xxx celkem 100 xx xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx nemocničních xxxxxxx, xxxxxxxxxxxxx zákroků xxxx xxxxxxxxxx xxxxxxxxxxxxxx metod.

M3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx následující:

1. Použití xxxxxxxx xxxxxxxxxx kyselin xxxx xxxxxx xxxxxxx;

2. Xxxxxxx geneticky produkovaných xxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxx x/xxxx k xxxxxxxxxxxx xxxx epigenetické xxxxxxxx xxxxxx xxxxxxx.

3. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;

XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx S0 xx X5 a X1 xx M3 xxxxxxxxx xxxx

xxxx Xxx Xxxxxxx xxxxxxxx i xxxxxxxxxxx skupiny:

ZAKÁZANÉ LÁTKY

S6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx jejich případných xxxxxxxxx xxxxxxx, xxxx. x- x X-, xxxx zakázaná.

Stimulancia xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx /4-fenylpiracetam (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (x-);

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxxx;

x-xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx.

Xxxxxxxxxxxx, které xxxx xxxxxxxx uvedeno x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx.

Xxxxxxxx (xxx xx x xxxxxxxx xxxxx na ně):

Adrenalin (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (parahydroxyamfetamin);

isomethepten;

katin**;

katinon a xxxx analoga (xxxx. xxxxxxxx, xxxxxxxxx x xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx (xxxxxxxxxxxxx);

xxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxx*****;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X výjimkou:

• klonidinu

• derivátů xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx/xxxxxx xxxxxxx x stimulancií xxxxxxxxxx xx Monitorovacího xxxxxxxx xxx xxx 2018*.

* Xxxxxxxxx, fenylefrin, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: Xxxx xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2018 x nejsou xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Xxxxx: je xxxxxxxx xxxxx při xxxxxxxxxxx vyšší xxx 5 mikrogramů x 1 xx xxxx.

*** Xxxxxxx x methylefedrin: xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx xxxx.

**** Xxxxxxxxx (xxxxxxxxx): není xxxxxxx xxx xxxxxxxx xxxxxx, např. xxxxx, xxxx aplikace nebo xxxx podání společně x lokálními xxxxxxxxxx.

***** Xxxxxxxxxxxxx: xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x xxxx je xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx kanabinoidy xxxx zakázané:

• Přírodní kanabinoidy, xxxx. xxxxx, xxxxxx x xxxxxxxxx.

• Xxxxxxxxxx xxxxxxxxxxx, xxxx. xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxx xxxxxxxxxxxxxx.

Xxxxx: xxxxxxxxxxxx

X9. GLUKOKORTIKOIDY

Všechny xxxxxxxxxxxxxxx xxxxxxxx orálně, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx xxxx zakázané.

Včetně, xxx ne x xxxxxxxx xxxxx xx xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX XXXXXXXX X&xxxx;XXXXXXXX XXXXXXXX

X1. XXXX-XXXXXXXXX

Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx, x xxx xx to xxxxxxxx x Xxxx xxxxxx.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxx (xxxxxxx xxxxxxxxxx) (WCBS)

• Golf (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (XXX) - xxxxx na xxxxxx x akrobatické xxxxxxxx-xxxxx x X-xxxxx, x xxxxxxxxx X-xxxxx x "xxx air"

• Podvodní xxxxxx (xxxxxxxxx xxxxxxxx) (XXXX) x xxxxxxxxxxxx konstantní xxxx x ploutvemi xxxx xxx ploutví, xxxxxxxxx apnoe x xxxxxxxxx xxxx bez xxxxxxx, xxxx xxxxxxxxx, xxxx blue, xxxxxxxxxxxx, xxxxxxxx xxxxx, xxxxxxx xxxxxxxx na terč x xxxxxxxxxx váha.

• Střelba (XXXX, XXX)*

• Xxxxx (XXX)

* Xxxxxxxx xxxx Mimo xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx xx x xxxxxxxx xxxxx xx xx.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 36/2019 Xx. x. x. nabyl účinnosti xxxx 26.7.2019.

Xxxxxx předpis x. 36/2019 Xx. x. x. xxx xxxxxx právním xxxxxxxxx č. 32/2023 Sb. m. s. x xxxxxxxxx xx 22.8.2023.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx v xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx derogační změna xxxxx xxxxxxxxx právního xxxxxxxx.

1) Xxxxxxxxxxx úmluva xxxxx xxxxxxx xx xxxxxx, xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx, xxxx xxxxxxxxx x xxxxxxxxx xxxxx a x xxxxxxxxx xx xxxxxxx xxxxxx pod č. 58/2007 Sb. m. s.

Xxxx xxxxx xxxxxxxx Xxxxxx xx xxxxxxx jazyka xxxx vyhlášeno xxx č. 46/2008 Sb. m. s.